Article
Cytoskeletal agents: future option for reducing IOP?
New Orleans—Cytoskeletal agents, which increase outflow facility in the trabecular meshwork, are one of the drug classes that could expand the pharmaceutical options available to reduce IOP, said Carl B. Camras, MD, professor, chairman, and director of the glaucoma service, department of ophthalmology, University of Nebraska Medical Center, Omaha.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
